Optimal Stopping Ages for Colorectal Cancer Screening
In this economic evaluation, age, sex, screening history, comorbidity, and future screening modality were associated with the clinical outcomes, cost-effectiveness, and optimal stopping age for CRC screening. These results can inform guideline development and patient-directed informed decision-making.
Authors
- Ronit R. Dalmat (ORCID: https://orcid.org/0000-0002-6959-0817)
- Christopher D. Jensen (ORCID: https://orcid.org/0000-0001-8001-1284)
- Reinier G.S. Meester (ORCID: https://orcid.org/0000-0003-4645-1221)
- Jessica Chubak (ORCID: https://orcid.org/0000-0003-1630-9021)
- Douglas A. Corley (ORCID: https://orcid.org/0000-0001-6132-5165)
- Natalia Udaltsova (ORCID: https://orcid.org/0000-0002-0679-4310)
- Matthias Harlass
- Rosita van den Puttelaar (ORCID: https://orcid.org/0000-0003-2216-6557)
- Nicholson Collier (ORCID: https://orcid.org/0000-0002-2376-4156)
- Jonathan Ozik (ORCID: https://orcid.org/0000-0002-3495-6735)
- Iris Lansdorp‐Vogelaar (ORCID: https://orcid.org/0000-0002-9438-2753)
Institutions
- Argonne National Laboratory (US)
- Kaiser Permanente (US)
- Kaiser Permanente Washington Health Research Institute (US)
- University of Washington (US)
- Erasmus MC (NL)
- University of Chicago (US)
- Kaiser Permanente San Francisco Medical Center (US)
- Freenome (United States) (US)
- Stanford University (US)
Publication Details
- Journal
- JAMA Network Open
- Published
- 2024-12-19
- DOI
- https://doi.org/10.1001/jamanetworkopen.2024.51715
- Citations
- 4
- Primary Topic
- Colorectal Cancer Screening and Detection
- Type
- article
- Field-Weighted Citation Impact
- 1.13
Funders
- U.S. Department of Energy
- Kaiser Permanente
- National Institutes of Health
- Office of Science
- National Cancer Institute
- Argonne National Laboratory